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Abstract
Background: Subtilisin-like Proprotein Convertase 7 (SPC7) is a member of the subtilisin/kexin family of pro-protein
convertases. It cleaves many pro-proteins to release their active proteins, including members of the bone morphogenetic
protein (BMP) family of signaling molecules. Other SPCs are known to be required during embryonic development but
corresponding data regarding SPC7 have not been reported previously.
Methodology/Principal Findings: We demonstrated that Xenopus SPC7 (SPC7) was expressed predominantly in the
developing brain and eye, throughout the neural plate initially, then more specifically in the lens and retina primordia as
development progressed. Since no prior functional information has been reported for SPC7, we used gain- and loss-of-
function experiments to investigate the possibility that it may also convey patterning or tissue specification information
similarly to Furin, SPC4, and SPC6. Overexpression of SPC7 was without effect. In contrast, injection of SPC7 antisense
morpholino oligonucleotides (MO) into a single blastomere at the 2- or 4-cell stage produced marked disruption of head
structures; anophthalmia was salient. Bilateral injections suppressed head and eye formation completely. In parallel with
suppression of eye and brain development by SPC7 knockdown, expression of early anterior neural markers (Sox2, Otx2,
Rx2, and Pax6) and late eye-specific markers (b-Crystallin and Opsin), and of BMP target genes such as Tbx2 and Tbx3, was
reduced or eliminated. Taken together, these findings suggest a critical role for SPC7–perhaps, at least in part, due to
activation of one or more BMPs–in early patterning of the anterior neural plate and its derivatives.
Conclusion/Significance: SPC7 is required for normal development of the eye and brain, possibly through processing BMPs,
though other potential substrates cannot be excluded.
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Introduction
The role of Subtilisin-like Proprotein Convertases (SPCs) is well
established in developmental processes, primarily by loss-of-
function studies in various systems [1]. It is thought that their
primary function in this context is to cleave growth factors
belonging to the TGF-ß superfamily, at the recognition sequence
RXXR, to their mature, biologically active forms. Previously, we
evaluated the expression patterns of known Xenopus SPCs to
determine which of these enzymes might play a role in patterning
of the developing joint or body axis [2,3]. We found that the
mRNA expression pattern of Xenopus SPC7 (also called PC7) was
inconsistent with a role in either of these processes. Instead, its
localization during early development suggested the possibility that
it might participate in patterning of specific anterior structures.
Here we report that loss of function of SPC7 in Xenopus leads
to diminished anterior structures, including the mid- and
forebrain, and anophthalmia (in which both lens and optic
cup formation are suppressed). To assess how SPC7 fits into the
developmental pathway controlling the formation of these
structures, we examined the expression of several genes
implicated in the early and late development of the brain and
the eye. Since BMPs are among the best-studied SPC substrates
and are known to participate in eye development, we also
examined expression of BMP response genes and found it to be
diminished. These results are consistent with a role for SPC7
upstream of the BMPs thought to be involved in early stages of
brain and eye development.
Results
SPC7 is the Presumed Ortholog of Mammalian SPC7
The cDNA used in this study contained an open reading frame
of 2,262 bp. The amino acid sequence is presented and compared
with that of human SPC7 in Figure 1. The overall amino acid
identity was 65% (91% in the catalytic domain, 68% in the
proprotein convertase domain); all other SPCs were substantially
less similar in primary sequence.
SPC7 Shows Both Maternal and Zygotic Expression in
Xenopus
Real-time PCR analysis revealed that SPC7 was expressed from
stage 0 to 40 (the latest stage analyzed, Figure 2A). The highest
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decreased until midgastrulation and increased thereafter.
Whole-mount hybridization in situ demonstrated SPC7 expres-
sion in the early neural plate at stage 13 (Figure 2B-C). The SPC7
signal for early stage embryos was too faint for analysis of
histological sections; expression in various germ layers was
evaluated in hemisected embryos to obviate this. The stage 13
hemisected embryo shown in Figure 2D displayed detectable
expression of SPC7 in the ectoderm, while no staining was evident
in the underlying mesoderm. By the mid to late neural fold stage
(Figure 2E-H), expression was apparent in the neural and head
folds; punctate nuclear staining in 2E and H, consistent with
transcriptional bursts, was prominent in scattered cells. Sections
cut through stage 18 embryos embedded in JB4 resin displayed
similar staining patterns to the stage 13 hemisected embryos we
evaluated; staining was evident in the sensorial layer of the
neuroectoderm, but not in the underlying somitogenic mesoderm
(Figure 2H). By stage 22, staining was observed in the eye, cement
gland, brain, and neural tube (Figure 2I-J). At stage 26, increased
staining intensity was evident in the retina, lens, cement gland, otic
vesicle, and somites (Figure 2K). By stage 32, SPC7 staining
remained in these structures (Figure 2L). At this later stage the
staining became more prominent in the lens, primarily due to
increased staining contrast via decreased retinal expression
(Figure 2L). To further evaluate these findings over-stained
embryos from the whole mount in situ experiment were embedded
in JB-4 resin and sectioned through the head, revealing that at
later stages (35–37) SPC7 staining had become specific to the lens
of the eye (Figure 2M-N). These data were confirmed by
hybridization to paraffin sections (Figure 2O-R).
SPC7 Loss of Function Results in Diminished Anterior
Structures and Anophthalmia
Injection of 300 pg SPC7 mRNA into a single blastomere at
either the two or four cell stage produced no detectable
abnormalities in phenotype (data not shown), consistent with the
expectation that constitutive gene expression levels are sufficient to
promote maximal cleavage of the enzyme’s substrate(s). We used
antisense morpholino oligonucleotides (antisense-MOs; reviewed
in [4,5]) to evaluate loss of SPC7 function.
We examined the effects of unilateral injections of SPC7
antisense-MO at the two cell stage and also at the four cell stage;
results were identical for both (Figure 3A, B). The effect of the
SPC7 antisense-MO was dose-dependent. At the 30 ng dose
(Figure S1), we observed a small eye phenotype in 68% - 75% of
the injected embryos (5 separate experiments; a total 143 of the
196 viable injected–i.e., fluorescein positive–embryos). At the
30 ng dose, lens tissue was totally absent in all embryos
examined, but small clusters of cells without discernable retinal
layers were present (Figure S1C). For the 90 ng dose (8 separate
experiments), a totally anophthalmic phenotype was observed in
83%–90%, or 239 of 267 total viable injected embryos. At this
dose the effects were more pronounced; eyes were essentially
completely absent, though small layers of cells consistent with
optic cup rudiments could be discerned in some embryos. The
mesencephalon was also absent on the injected side (Figure 3A-
E). Histological evaluation of embryos injected with 90 ng
control-MO or SPC7 antisense MO is presented in Figure 3F
and Figure 3G, respectively. Sections taken through the entire
embryo were examined in each case. As noted previously, the
eye and brain were hypo- or dysmorphic in injected embryos,
but the otic vesicle and pronephros appeared normal, as did all
more posterior structures. Since no nonspecific toxicity was
observed at 90 ng, all subsequent experiments–including all
rescue experiments done to exclude possible off-target effects–
were conducted with 90 ng MO.
Bilateral injection of SPC7-MO (both dorsal blastomeres at the
two or four cell stages) completely suppressed formation of
externally visible head structures in all embryos examined
(3 separate experiments; 91 viable injected embryos); in histolog-
ical sections, both eyes and the midbrain were absent (data not
shown). Bilateral injection of control morpholino had no
observable effect.
All of the experiments were repeated with a second SPC7
antisense morpholino oligonucleotide and the results were
identical (2 separate experiments; 70 of 86 viable embryos
evaluated displayed the eye phenotype). The control MO had
no effect: of 159 fluorescein positive embryos evaluated, none
showed detectable abnormalities.
Loss of Function Effect of SPC7 Antisense Morpholino
Oligonucleotide is Specific
To confirm the specificity of SPC7 antisense-MO further, we
created a truncated Xenopus SPC7 mRNA that could not hybridize
to either of the antisense-MOs we tested (Figure 4A, B). 300 pg of
this mRNA were able to rescue the eyeless phenotype completely
in all embryos examined when coinjected with either of the anti-
sense morpholinos (Figure 4F-H). As indicated previously, only the
90 ng dose was used in the rescue experiments (3 separate
experiments; a total of 106 healthy injected embryos were scored;
eye abnormalities could not be detected in any embryo injected
with the truncated SPC7 mRNA and antisense-MO). Results were
identical with both morpholino oligonucleotides tested. Controls
injected with SPC7-MO alone were included routinely to verify
that the morpholino was active (Fig. 4C-E).
Loss of Function of SPC7 Does Not Affect Mesodermal
and Posterior Neuroectodermal Marker Expression
Patterns
We evaluated the regional specificity of SPC7 action by
examining the expression of posterior neuroectodermal (Hox B9)
and mesodermal (Muscle Actin) markers in SPC7- MO unilater-
ally injected embryos. Both the injected and uninjected sides of the
embryo showed normal expression patterns for these markers
(Fig. 5A-D; embryos shown here were injected at the four cell
stage).
SPC7 Loss of Function Suppresses Markers for Anterior
Patterning of Neural Tissues and Early Eye Development
Many transcription factors have been implicated in the anterior
patterning of neural tissues including the eye [6,7,8,9]. These
include: Sox2 (sex determining region Y-box 2), which is expressed
in the anterior neural plate and placodal tissues and is essential for
crystallin promoter activation [10,11]; Rx2a (retinal homeobox2a),
an early eye marker essential for specification, survival, and
proliferation of retinal cells in eye development [7,8]; Otx2
(orthodenticle homeobox 2), one of the earliest genes to originate
from the anterior neural plate [6,10]; and Pax6 (paired box gene 6)
[12], the vertebrate homolog of Drosophila eyeless [13]. These have
Figure 1. Sequence of SPC7. The amino acid sequence is aligned with that of human SPC7. Identities are highlighted in yellow, similarities in
green, the catalytic domain in magenta, and the proprotein convertase domain in cyan.
doi:10.1371/journal.pone.0039380.g001
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PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e39380Figure 2. Expression of SPC7 mRNA in Xenopus embryos at different developmental stages. (A) Real-time PCR. (B-N) Whole mount
hybridization in situ (in panels B, C, E, and I-L, anterior is to the left. Dotted lines in C, E, G, and L indicate the approximate plane for images in D, F, H,
and M, respectively). (B-C) Lateral (B) and dorsal (C) views of a stage 13 embryo showing staining in the early neural plate. (D) Hemisected stage 13
embryo displaying detectable expression of SPC7 in the sensorial layer of the neuroectoderm, but not in the underlying somitogenic mesoderm. (E)
Dorsal view of stage 16 embryo showing SPC7 staining in the neural folds and presumptive eye field. (F) hemisected midneurula (stage 16) showing
Xenopus SPC7
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specification. Opsin, a major protein in the photoreceptor cells, is
a useful marker for terminal differentiation of the retina; it first
appears in Xenopus at stage 29 and is expressed thereafter [14]. b-
Crystallin is the major structural protein of the lens, and so is a
well- established marker for the differentiating cells within the
posterior lens vesicle, which first becomes detectable at stages 26–
27, and for the mature lens [15].
To evaluate molecular correlates of the phenotype, we
examined these markers in embryos injected unilaterally with
SPC7-MO by hybridization in situ. Sox2 expression in neurula
stage embryos was substantially decreased on the injected side,
compared with the uninjected side or with the control-MO
injected embryos (Figure 6A). In later stage embryos, Sox2
expression in the retina was nearly absent on the injected side; in
the midbrain and neural tube, staining was markedly reduced
compared with the uninjected side or with control-MO injected
embryos (Figure 6A). Similarly to Sox2, Otx2 expression in the
MO-injected side was markedly reduced in neurulas, and
undetectable in the eye and midbrain of somite and tadpole stage
embryos; the contralateral uninjected side and control-MO
injected embryos showed the normal expression pattern
(Figure 6D). Rx2a was undetectable in the retina on the injected
side, while the uninjected side showed normal expression
(Figure 6B). Results were similar for Pax6; SPC7-MO significantly
suppressed observable staining in the eye and caused reduced
expression in the midbrain (Figure 6C).
Consistent with the near total lack of eye tissue observed at the
90 ng MO dose, b- Crystallin and Opsin transcripts could not be
detected on the injected side of stage 33–35 embryos by
hybridization in situ in frontal sections through the eye field (not
shown). Since some presumptive optic vesicle tissue remained at
the 30 ng dose (Figure S1C), we also evaluated expression of both
markers in these embryos. Here also, expression of these terminal
differentiation markers was undetectable on the injected side,
while the expression pattern on the uninjected side and in control-
MO injected embryos was normal (Figure 6E, F).
SPC7 Loss-of-Function Suppresses BMP Response Genes
One well-appreciated function of the SPCs is to process BMPs
[16], which are thought to act early in the sequence of events
leading to specification of anterior neural structures including the
eye [9]. We therefore evaluated BMP signaling with hybridiza-
tion in situ for the BMP response genes Tbx2 and Tbx3 [17,18]
which are closely related T-box proteins that have been
implicated in development of a number of different tissues
including the eye [19]. SPC7-MO injection resulted in total loss
of Tbx2 expression in the eye, frontonasal region, and branchial
arches; expression in the otic vesicle and cranial ganglia was
unaffected (Figure 7A, B). Tbx3 expression was diminished in the
branchial arches on the MO-injected side, and was totally
undetectable in the eye region (Figure 7C, D).
Discussion
The importance of the Subtilisin-like Proprotein Convertases in
controlling the activity of TGF-ß superfamily proteins is now well-
established [16]. Recently, we presented evidence that anatomi-
cally restricted overlap of the expression domains of these
proteases and growth factors provides an additional level of
regulation. In these studies, we evaluated the potential of known
SPCs to participate in patterning of the limb [3] and body axis [2].
SPC7 was excluded on the basis of its temporal and spatial
expression patterns; its expression in the limb cannot be detected
by RT-PCR, and SPC7 is expressed in the blastula at a site remote
from the dorsal vegetal endoderm [2,3]. However, its discrete
expression pattern suggested the possibility that this protease might
participate in specification of anterior structures (Figure 2).
The loss of function data presented here indicate a requirement
for field- specific processing by SPC7 during development of the
eye and brain; unilateral injection of antisense morpholino
oligonucleotides produced dose-dependent loss of eye and brain
tissue. At the 90 ng dose, both lens and optic vesicle were absent in
all embryos evaluated (Figure 3E, G), and the brain was severely
hypomorphic; at 30 ng, the lens was absent but dysmorphic optic
vesicle tissue was present in some embryos (Figure S1C). We
consider non-target effects unlikely, since 1) injection of control
MO was consistently ineffective; 2) similar results were obtained
with two different non-overlapping antisense SPC7 oligonucleo-
tides; and 3) mRNA rescue of embryos injected with the 90 ng
dose of either MO oligonucleotide was complete (Figure 4A-E) in
every single embryo examined.
The near total suppression of the terminal eye differentiation
markers crystallin and opsin was consistent with the gross and
histological findings. Moreover, reduced expression of early
markers of brain and eye development (Sox-2 and Otx-2) by the
SPC7 antisense oligonucleotides in neurula stage embryos
(Figure 6) suggests that SPC7 is essential near the beginning of
events leading to specification of the anterior neural plate.
Suppression of these markers, as well as the BMP response genes
Tbx2 and Tbx 3 (Figure 7), would be consistent with existing
models [7,9] that place BMP signaling proximal to these
transcription factors in the specification of the anterior nervous
system. Thus, the absence of eye and brain resulting from SPC7
knockdown that we observed likely resulted from a more general
disruption of these early patterning events.
Approximately 3500 mammalian secretory proteins, including
growth factors and their receptors, are subjected to limited
proteolysis by one or more members of the SPC family [20]. The
complexity of substrate processing, based on redundancy and
specificity of SPCs, is variable depending on the tissue. The well
established role of SPCs for BMP processing in many develop-
mental processes and the widely-appreciated requirement for
BMP signalling in eye development prompted us to examine these
factors.
Our data cannot exclude the possibility that SPC7 may act on
non-BMP substrates that play a role in eye and/or forebrain
staining in the sensorial ectoderm (arrow). (G) Antero-dorsal view of a late neural fold (stage 18) embryo showing staining in the anterior part of
neural plate and anterolateral edges. (H) Plastic section through over-stained embryo showing staining in neuroectoderm. Lateral (I) and dorsal (J)
views of a stage 21–22 embryo showing prominent staining in the eye, cement gland, brain, and neural tube. (K) Lateral view of stage 26 embryo
showing SPC7 expression in the retina, lens, cement gland, otic vesicle, and throughout the head and somites. (L) At stage 32, staining in the lens
became more prominent, primarily because expression in the retina decreased substantially. (M) Plastic section of over-stained stage 35 embryo
showing specific SPC7 localization in the lens. (N) Enlarged view of boxed area shown in M. (O-R) Stage 30–32 (O, P) and stage 35–37 (Q, R) paraffin
sections analyzed for SPC7. (O) Total fluorescence. (P) Same section as in O showing specific SPC7 staining in retina and lens (Fast Red). (Q) Total
fluorescence. (R) Same section as in Q showing specific SPC7 fluorescent staining localized to the lens. (NC=Notochord; EE=Epithelial Layer of
Neuroectoderm; SE=Sensorial Layer of Neuroectoderm; SM=Somitogenic Mesoderm).
doi:10.1371/journal.pone.0039380.g002
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PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e39380Figure 3. SPC7 antisense morpholino oligonucleotide causes dose-dependent disruption of eye and brain development. (A, B)
Embryos injected unilaterally with antisense SPC7-MO at the two cell (A) or four cell stage (B). Injected side is shown on the left. Both the two cell and
four cell stage loss-of-function SPC7 experiments resulted in the same phenotype: lack of eye, lack of branchial arches, and diminished head
structures on the MO-injected side. The morphology of the rest of the embryo appeared normal. (C) Dorsal view of tadpole-stage embryo injected at
the four cell stage with 90 ng MO; the eye appears to be completely absent on the injected side. (D) Same embryo as in C showing MO location on
the left. (E) Frontal section of embryo in C and D showing total loss of eye and mesencephalon on the SPC7-MO injected side. The uninjected side was
unaffected. Arrows 1 and 2 show presumptive eye field and mesencephalon, respectively, on the MO injected side. In each experiment, embryos
injected with control MO developed normally (not shown). (F, G) Histological analysis of control-MO injected (F) and SPC7-MO unilaterally-injected (G,
injected side to the left) stage 35 embryos. The planes of section presented are shown diagrammatically at the top. As noted previously, the eye and
brain are severely dysmorphic on the injected side; the otic vesicle and pronephros appear normal. (L= Lens; R=Retina; NC=Notochord;
MC=Mesencephalon; RC=Rhombancephalon; SC= Spinal Cord; OV=Otic Vesicle; PN=Pronephros; EF=Eye Field).
doi:10.1371/journal.pone.0039380.g003
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in these processes is substantial. BMP4 and BMP7 are both
known to be substrates of SPC7. They are required for eye
patterning and are thought to act in early stages of this process.
BMP7 gene targeting experiments in the mouse lead to a
variable phenotype that ranges from mild microphthalmia to
anopthalmia [21,22]. In severely affected null mice, the lens
placode fails to form and the placodal phase of Pax6 expression
is lost [23]. These findings indicate that BMP7 plays an
important role upstream of Pax6 during lens placode formation
and specification. BMP42/2 null mutants exhibit defects in lens
induction and lens-specific Sox2 expression is diminished [24].
Even though BMP7 and BMP4 have overlapping expression
patterns in the eye and BMP72/2 and BMP42/2 mice display
Figure 4. 59 sequence of SPC7. (A) 59 sequence of SPC7 and antisense morpholino oligonucleotides. Sequences corresponding to SPC7 MOs 1 and
2 are shown in green and magenta, respectively. Start codon is underlined. Arrow denotes 59 primer used to construct synthetic mRNA used in rescue
experiments. (B) Sequences of antisense morpholino oligonucleotides. (C, D) Bright and dark field images of stage 37 SPC7 antisense morpholino-only
control embryo showing anophthalmic SPC7-MO phenotype on injected side. (E) Histological section through SPC7-MO embryo; note lack of
distinguishable eye structures on the injected side and severe mesencephalic hypoplasia. (F, G) Bright and dark field images of stage 37 embryo
coinjected with SPC7 antisense morpholino oligonucleotides and synthetic rescue mRNA, showing normal morphology on the injected side. For all
rescue experiments, we used the 90 ng dose. Complete rescue as shown in (F-H) was observed in all embryos in each of three separate experiments
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between these two mutants. In particular, Pax6 expression is lost
in BMP72/2 mutants [23] but not in BMP42/2 mice [24].
These observations indicate that BMP4 and BMP7 may have
non-redundant functions in eye development [9]. SPC7 loss-of-
function significantly decreased eye-specific expression of Pax6
(Figure 6D). Therefore, the action of SPC7 cannot be explained
on the basis of BMP4 activation alone; one possibility is that it
also is required for processing of BMP7 in the anterior neural
fold. Moreover, both BMP4 and BMP7 null mice form optic cup
tissue [21,24], whereas at high doses of SPC7-MO, these tissues
are absent. Another BMP, Growth and Differentiation Factor 6
(GDF6) may also be a substrate for SPC7; GDF6 loss-of-function
produces small eyes in Xenopus [25]. However, since the SPC7
loss of function phenotype we observed is much more severe
than that reported for GDF6- depleted embryos, it is clear that
this BMP cannot be its only substrate. Thus, it is unlikely that
the apparent requirement for SPC7 can be explained by its
action on any one of these growth factors alone, but rather on
some combination of BMP4, BMP7, and possibly GDF6, as well
as other yet undetermined substrates. As indicated previously, it
is possible that non-BMP substrates for SPC7 (e.g., pro-EGF,
[20]) may also be important in eye and/or forebrain develop-
ment, but there is currently little direct evidence for this.
Thus, coexpression of SPC7 with BMPs required in anterior
neural development may represent another situation in which one
level of control over growth factor activity is exerted by virtue of
anatomically restricted processing of growth factors to a specific
developmental field. This is analogous to our earlier findings with
CDMP-1/GDF-5 [3] and Vg1 [2]. There is a description of
unpublished data indicating that SPC7 loss of function does not
produce a phenotype in mice [26]. Our data make it clear that the
situation is different in Xenopus, so the notion that SPC7 is not
required during development cannot be generalized to other
vertebrates. However, both BMPs and SPCs have substantial
functional redundancy [16], and it is possible that such compen-
satory mechanisms may be more advanced in mammals than in
amphibians. Resolution of this question may be an appropriate
topic of further study.
Figure 5. Loss of SPC7 function does not affect mesodermal and posterior neuroectodermal marker expression patterns. Whole
mount hybridization in situ of embryos injected unilaterally with 90 ng SPC7 morpholino. Injected sides are shown to the left. (A, B) Lateral views of
stage 35 embryo showing that muscle actin (dorsal mesoderm) staining was equally visible in both the injected and uninjected sides of the embryo.
(C, D) Lateral views showing that HoxB9 (posterior neuroectoderm) expression was equally apparent in the posterior dorsal region of the embryo in
both the injected and uninjected sides.
doi:10.1371/journal.pone.0039380.g005
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Embryo Manipulations
Frogs and their embryos were maintained and manipulated
using standard methods [27,28]. All embryos were staged
according to Nieuwkoop and Faber [29] and Keller [30]. Injection
experiments were performed by standard procedures as described
previously except embryos were maintained in 0.3x MMR
supplemented with 3% Ficoll 400 [31] during and immediately
following injection. Dorsal and ventral blastomeres were identified
by size and pigment variations [29]. All injection experiments were
carried out at both the two and four cell stage unless otherwise
noted. For unilateral injections, mRNA and morpholino-antisense
oligonucleotides were injected into a single dorsal blastomere. For
bilateral injections, injections were into two blastomeres at the two
or four cell stage. All loss-of-function experiments included
control-MO injected embryos. Except as noted, all MO injections
(including rescue experiments) were done at the 90 ng dose, and
Figure 6. Loss of function of SPC7 diminishes expression of neural and eye markers. (A-D) Whole mount hybridization in situ of embryos
injected unilaterally with 90 ng SPC7 morpholino. Injected sides are shown to the right. (A) Frontal, dorsal, and lateral views showing Sox2 expression
in control (left) and SPC7-MO unilaterally injected (right) embryos. Early- (top row) and mid-neurula (second row) embryos showing diminished Sox2
staining on the SPC7 morpholino injected side, most obviously in the eye anlage but apparent throughout the head folds (arrows). The loss of
expression became more obvious at later stages. Row Three: antero-frontal view of stage 22 embryos. Sox2 staining was undetectable in retina, lens,
and neural tube, and was reduced in the midbrain on the injected side. Row 4: dorsal view of the same embryos showing that Sox2 staining was
absent in the neural tube on the injected side. Bottom row: Stage 35 embryo showed complete loss of Sox2 staining in the eye on the injected side.
(B) Lateral views showing Rx2a expression was not detectable on the injected side (arrow). (C) Lateral views showing Pax6 expression pattern in
control (left) and injected (right) stage 26–27 embryos. Pax 6 staining was absent in the eye field on the injected side (arrow). (D) Otx2 expression in
uninjected control (left) and SPC7-MO unilaterally injected (right) embryos. Top row: antero-dorsal view of stage 14 embryos showing significantly
diminished Otx2 expression on the injected side (arrow). Bottom row: Lateral views of control (left) and SPC7 MO-injected (right) sides of the same
embryo showing barely detectable Otx2 expression on the injected side (arrow). (E, F) Frontal sections through the head of stage 35 embryos injected
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(or mRNA where appropriate).
Embryos were photographed with low angle oblique illumina-
tion and a Zeiss Stemi-6 dissecting microscope or with a Leica
DCF420 camera.
mRNA Quantitation (Real-Time PCR)
Total RNA was extracted using Trizol (Invitrogen) or the
RNeasy kit (QIAGEN). Quantitative real-time PCR analyses were
performed using the ABI 7900 sequence detection system. SPC7
and Histone specific primers were designed using Primer Express
software (SPC7 forward primer 59-CTG CGA GAA AAG GGA
GGA GAT-39, reverse primer 59-GCC CTG TGG CTT TGG
AAA-39. Histone forward primer 59-ACG CCG TCA CCT ACA
CAG AAC-39, reverse primer 59-ACC ACA TCC ATG GCG
GTA AC-39). SPC7 and Histone mRNA samples were first reverse
transcribed and then subjected to SYBR Green quantitative real-
time PCR. Known quantities of 10-fold dilutions of total input
cDNA were used to generate standard curves for each primer pair.
Relative amounts of each embryonic stage were determined in the
linear range according to their CT value. For each primer set,
melting curves were used to verify the correct PCR product.
Histone H4 mRNA levels were used for normalization. All PCRs
were performed in triplicate.
Plasmids and Probes
The Xenopus SPC7 plasmid was as described previously [3];
Genbank accession number: EU879966). The following ESTs
were purchased from the Open Biosystems: Sox2 (clone id
3398743), Rx2a (clone id 7981599), Otx2 (clone id 6632834),
Pax6 (clone id 79800371), b-Crystallin (clone id 6879338), Opsin
(clone id 7019321), Tbx2 (clone id 6865037), Tbx3 (clone id
7980218), muscle actin (clone id 4409317), and HoxB9 (clone id
7982206). The poly A tails were removed with HindIII for Opsin
and Sox2 or with ApaI for Rx2a. The plasmids were then
religated. For Otx2 and Pax6, the poly A tail was removed by
digestion with SalI/BamHI or EcoRV/XhoI, respectively. The
poly A tail of Tbx2 was removed by EcoR1 digestion; the insert
was then subcloned into PCR4-TOPO (Invitrogen) and se-
quenced. For Tbx3, the poly A tail was removed by digestion
with EcoRV/Not1 and the plasmid religated. Finally, the Poly A
tails were removed with Kpn1 for muscle actin, or with PvuII and
Not1 for HoxB9. The plasmids were then religated. The b-
Crystallin EST did not contain convenient restriction sites; we
therefore amplified the open reading frame by PCR using
Figure 7. BMP target genes Tbx2 and Tbx3. Whole mount hybridization in situ of BMP target genes Tbx2 and Tbx3 in stage 33/34 embryos
injected unilaterally with 90 ng SPC7 morpholino. Injected sides are shown to the right. (A, B) Lateral view of embryos showing Tbx2 expression was
lost in the eye on the MO-injected side only (NR, neural retina; CG, cranial ganglion; OV, otic vesicle; BA, branchial arches; FN, frontonasal process).
(C, D) Lateral view of stage 33/34 embryos showing a similar result for Tbx3.
doi:10.1371/journal.pone.0039380.g007
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CGG GAA-39 and reverse, 59-GCA TCA TAT TGT AAA GTA
CAT CGG T-39. The product was subcloned into PCR4-TOPO.
Correct sequence and orientation were confirmed by bidirectional
sequencing of all plasmids.
Antisense Morpholino-oligonucleotides and Rescue
Constructs
Xenopus SPC-7 antisense (we used both 59- GATGTGATA-
CATTCTGGTGGCCCA T-39 and 59-GGCAGTCCAG-
CAAGTTCATCAGGAC-39 with similar results) and control
(59-TACCCGGTGGTCTTACATAGTGTAG-39) morpholino
oligonucleotides, tagged with fluorescein, were purchased from
Gene Tools. For mRNA rescue experiments, we amplified the
open reading frame of SPC7 with the primers: forward, 59-GAA
TGT ATC ACA TCC CTA TCT CCT -39; reverse, 59-TGC
CAC ATT CAG TCA TAT CAG GGT-39. The resulting cDNA
contained the complete open reading frame but lacked 11 bp of
59-UTR sequence present in the SPC7 morpholino oligonucleo-
tides and so could not form a stable hybrid with either
morpholino. This was subcloned into pCS2 and the sequence
verified as above.
Histology
Embryos were embedded in JB-4 resin according to manufac-
turer’s instructions, sectioned on a Leica RM2265 rotary
microtome at 2 or 5 microns, and mounted on SuperFrost Plus
slides (Fisher) to facilitate adherence during staining. To accen-
tuate the eye and clearly differentiate neural retina and lens from
other tissues, a method based on the Feulgen reaction followed by
counterstaining with Light Green and Orange G [32] was
modified for use in plastic sections as follows. Sections were rinsed
in 1 N HCl, hydrolyzed for ten minutes in 1 N HCl at 60uC, and
rinsed at RT in 1 N HCL followed by water. The sections were
then stained in Schiff reagent for 24–48 hours or in acidified
alcoholic basic fuchsin [33] for 30 minutes. Stained sections were
drained, rinsed 3 times in 0.5% potassium metabisulfite in 5%
HCL, and then rinsed with tap water. They were then fixed on a
hot plate at 80uC for at least 10 minutes. Sections were
counterstained with Light Green (0.2% in 95% ethanol) for
20 seconds followed by a water rinse, and then with Orange G
(0.2% in 0.2% phosphotungstic acid ) for 40 seconds. The staining
times were adjusted as needed to achieve optimum color
differentiation. Finally, slides were rinsed with water and air dried.
Hybridization in Situ
cRNA probes were produced using MEGAscript T3, T7, or
SP6 in vitro transcription kits (Ambion), incorporating digox-
igenin. For whole mount hybridization in situ on Xenopus embryos,
procedures outlined by Harland were followed [34], with
modifications as described [31]. For colorimetric detection, signals
were developed using alkaline-phosphatase conjugated antibodies
to digoxigenin and BM-Purple (Roche). Overstained embryos
were embedded in JB-4 resin (Polysciences, Warrington, PA) after
abbreviated infiltration (3610 min) and sectioned at 20 microns
with a Leica RM2265 rotary microtome.
Paraffin sections (7–10 mm) were prepared for hybridization in
situ using a standard protocol [35]. Prior to hybridization, sections
were incubated for 30 min at 90uC in 10 mM citrate buffer,
pH 6.0 to enhance antigenicity [36]. Hybridization was performed
at 60uC overnight in the presence of 1 mg/ml of probe. For
fluorescent detection, probes were labeled with digoxigenin and a
sheep alkaline- phosphatase conjugated anti-digoxigenin antibody
(Roche) was used in combination with Fast
TM Red (Sigma)
fluorogenic substrate. Confocal images (crystallin and opsin) were
obtained using a confocal Zeiss Imager Z1microscope with a
krypton-argon and blue diode laser. SPC7 detection was done with
a Nikon Eclipse 80i using MetaMorph image analysis software.
Supporting Information
Figure S1 SPC7 antisense morpholino oligonucleotide
causes dose-dependent disruption of eye and brain
development –30 ng dose. (A) Dorsal view of the head of a
stage 35 embryo injected unilaterally with 30 ng MO. The MO
injected side, to the left, failed to develop a normal eye. (B)
Localization of fluorescein tagged MO in same embryo. (C)
Frontal section of embryo shown in (A) and (B) showing a
disorganized neural retina and no lens (arrow). The right,
uninjected side was unaffected.
(TIF)
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